Pharmacodynamic Equivalence of a Decapeptyl 3-Month SR Formulation with the 28-Day SR Formulation in Patients with Advanced Prostate Cancer

Publisher： Karger

E-ISSN： 1663-2826|62|5|252-258

ISSN： 1663-2818

Source： Hormone Research in Paediatrics, Vol.62, Iss.5, 2004-11, pp. : 252-258

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide

By  

Neuroendocrinology, Vol. 80, Iss. 4, 2005-01 ,pp. : 244-251

Karger

Access to resources Recommend Favorite

Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation


By  

Hormone Research in Paediatrics, Vol. 87, Iss. 4, 2017-03 ,pp. : 224-232

Karger

Access to resources Recommend Favorite

Three-Month Sustained-Release Form of Triptorelin in Patients with Advanced Prostatic Adenocarcinoma: Results of an Open Pharmacodynamic and Pharmacokinetic Multicenter Study

By  

Hormone Research in Paediatrics, Vol. 50, Iss. 2, 1998-08 ,pp. : 89-93

Karger

Access to resources Recommend Favorite

Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France

By  

Neuroendocrinology, Vol. 89, Iss. 2, 2008-08 ,pp. : 217-222

Karger

Access to resources Recommend Favorite

Degarelix: A New Approach for the Treatment of Prostate Cancer

By  

Neuroendocrinology, Vol. 90, Iss. 3, 2009-07 ,pp. : 235-244

Karger

Access to resources Recommend Favorite